Cabaletta Bio (CABA) Aandeel Koers
Cabaletta Bio Koers
Cabaletta Bio aandeelkoers
Deze data ophalen via de Eulerpool API
100.000 requests/maand gratis · geen creditcard
Cabaletta Bio bedrijfsmodel & aandelenanalyse
Veelgestelde vragen over Cabaletta Bio
The business model of Cabaletta Bio Inc focuses on the development and commercialization of cell therapy products for the treatment of B cell-mediated autoimmune diseases. As a clinical-stage biotechnology company, Cabaletta Bio Inc aims to utilize its proprietary technology platform, the proprietary Chimeric AutoAntibody Receptor (CAAR) T-cell technology, to engineer T cells that can selectively eliminate autoreactive B cells. By targeting the underlying cause of autoimmune diseases, Cabaletta Bio Inc strives to provide potentially curative therapies for patients suffering from diseases such as mucosal pemphigus vulgaris and mucosal pemphigoid.
Cabaletta Bio Inc is primarily active in the biotechnology industry.
The main competitors of Cabaletta Bio Inc in the market include companies such as Passage Bio, Audentes Therapeutics, and Axovant Gene Therapies. These companies are also involved in the development and commercialization of novel gene therapies aimed at treating various diseases.
Cabaletta Bio Inc. is a biopharmaceutical company that focuses on the development of engineered T-cell therapies for patients with B cell-mediated autoimmune diseases. The company was founded in 2017, with its headquarters in Radnor, Pennsylvania, United States. Cabaletta Bio Inc. aims to harness the power of its proprietary CAR-T cell platform to create transformative therapies that selectively eliminate only the cells responsible for autoimmune diseases, while sparing healthy cells. With a strong emphasis on research and product development, Cabaletta Bio Inc. is dedicated to advancing innovative treatment options for patients suffering from severe autoimmune disorders.
Cabaletta Bio Inc has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2018, raising capital to support its innovative cell therapy programs. Additionally, Cabaletta Bio has entered into strategic partnerships, including a collaboration with Medison Pharma, to accelerate the development and commercialization of potential therapies. Moreover, the company has made progress in advancing its lead product candidate, DSG3-CAART, through clinical trials. Cabaletta Bio Inc's dedication to advancing precision engineered cell therapies has positioned it as a promising player in the field of immune-mediated diseases.
Cabaletta Bio Inc is primarily present in the United States.
Cabaletta Bio Inc represents a strong commitment to developing transformative therapies for patients with B cell-mediated autoimmune diseases. The company's core values focus on innovation, scientific excellence, and dedication to improving patient lives. Cabaletta Bio Inc adopts a patient-centric approach, aiming to deliver novel, scalable, and curative Chimeric AutoAntibody Receptor (CAAR) T-cell therapies. The company's corporate philosophy revolves around collaboration, conducting robust research, and harnessing cutting-edge technologies to address unmet medical needs. Cabaletta Bio Inc strives to achieve clinical advancements, build strategic partnerships, and contribute to the overall advancement of precision medicine in the field of autoimmune diseases.
16 analisten beoordelen het aandeel Cabaletta Bio momenteel: 13 adviseren kopen, 3 houden en 0 verkopen. Voor 2026 verwachten analisten dat Cabaletta Bio een omzet van 2,50 Miljoen USD en winst per aandeel van -1,28 USD behaalt.
Omgezet tegen de huidige wisselkoers noteert het aandeel Cabaletta Bio op 1,16 EUR (1,29 USD).
Het aandeel Cabaletta Bio (CABA) is genoteerd aan 1 beurzen, waaronder: NASDAQ (CABA).
The company Cabaletta Bio Inc is a biopharmaceutical company that develops personalized therapies for patients with rare hereditary autoimmune diseases. Cabaletta Bio's business model is based on the use of CAR-T cell therapies tailored to the individual needs of each patient. Cabaletta Bio Inc debuted on the Nasdaq stock exchange in 2018 to finance the company's further growth. Through the Initial Public Offering (IPO), Cabaletta Bio raised $74 million and valued the company at approximately $390 million. Cabaletta Bio's research focuses on three main areas. Firstly, the identification of rare hereditary autoimmune diseases and the development of personalized CAR-T cell therapies. Secondly, the discovery of innovative technologies for CAR-T cell manufacturing. And thirdly, collaboration with leading researchers, universities, and hospitals to improve CAR-T cell therapies. Currently, Cabaletta Bio's key products are the AUTO1 CAR-T cell therapies developed for the treatment of patients with cutaneous T-cell lymphopenia (CTCL) and mucous membrane pemphigoid (MMP). AUTO1 is a personalized therapy manufactured from the patient's own T-cells. The CAR-T cells are designed to specifically target the disease-causing cells of the patient. Cabaletta Bio has also developed a platform technology that enhances the effectiveness of CAR-T cell therapy. This platform, called HeLaMo, is based on the use of helper T-cells to amplify the activity of CAR-T cells in the patient's body. HeLaMo also improves the safety and efficiency of treatment. Cabaletta Bio also has an extensive pipeline of therapies in development targeting various autoimmune diseases. These include autoimmune diseases of the skin, eyes, and central nervous system. Cabaletta Bio's business model is based on partnerships with leading institutions and regulatory agencies. The company has partnerships with the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Cabaletta Bio has also formed a strategic partnership with Regeneron Pharmaceuticals to harness the potential of Cabaletta Bio's technology platform in the field of autoimmune diseases of the eye. Cabaletta Bio is a rapidly growing company with a promising portfolio of personalized CAR-T cell therapies. The company is committed to improving the lives of patients with rare autoimmune diseases and revolutionizing the treatment of autoimmune diseases.
De verwachte omzet van Cabaletta Bio bedraagt 2,50 Miljoen USD. Deze cijfers zijn gebaseerd op huidige financiële gegevens en weerspiegelen de bedrijfsresultaten van het bedrijf.
De verwachte winst van Cabaletta Bio bedraagt -131,11 Miljoen USD. De nettowinst weerspiegelt de rentabiliteit van het bedrijf na aftrek van alle kosten.
De koers-winstverhouding (P/E) van Cabaletta Bio bedraagt momenteel -1,01. De P/E-ratio vergelijkt de huidige aandeelkoers met de winst per aandeel en helpt beleggers de waardering van het Cabaletta Bio-aandeel in te schatten.
De koers-omzetverhouding (P/S) van Cabaletta Bio bedraagt momenteel 52,97. De P/S-ratio vergelijkt de marktkapitalisatie met de jaarlijkse opbrengsten en dient als waarderingsmaatstaf voor het Cabaletta Bio-aandeel.
De Eulerpool Kwaliteitsscore voor Cabaletta Bio is 3/10.
De ISIN van Cabaletta Bio is US12674W1099. De ISIN (International Securities Identification Number) is een wereldwijd unieke identificatie voor wertpapieren.
De WKN van Cabaletta Bio is A2PTTB. De WKN (Wertpapierkennnummer) is een zescijferig Duits identificatienummer voor wertpapieren.
Het tickersymbool van Cabaletta Bio is CABA. Onder dit beurstickersymbool wordt het Cabaletta Bio-aandeel op de beurs verhandeld.
Cabaletta Bio aandeel
Cabaletta Bio Peer Group
Cabaletta Bio Ticker
Cabaletta Bio FIGI
Alle fundamentals en diepgaande analyse van Cabaletta Bio
Onze aandelenanalyse van het Cabaletta Bio-aandeel omvat belangrijke financiële kerncijfers zoals de omzet, de winst, de P/E-ratio, de P/S-ratio, de EBIT, evenals informatie over het dividend. Daarnaast bekijken we aspecten zoals aandelen, marktkapitalisatie, schulden, eigen vermogen en verplichtingen van Cabaletta Bio. Als u meer gedetailleerde informatie zoekt over deze onderwerpen, bieden we op onze subpagina's uitgebreide analyses: